



Claims

1. The use of selective PDE9A inhibitors for producing medicaments for improving perception, concentration, cognitive processes, learning and/or memory.
5
2. The use as claimed in claim 1 for the prophylaxis and/or treatment of impairments of perception, concentration, cognitive processes, learning and/or memory.
10
3. The use as claimed in claim 2, where the impairment is a consequence of a disorder selected from the group consisting of dementia, stroke, craniocerebral trauma, Alzheimer's disease, Parkinson's disease, depression, or dementia with degeneration of the frontal lobes.
15
4. The use of PDE9A inhibitors for producing medicaments for the treatment and/or prophylaxis of diseases of the central nervous system which are amenable to therapy through influencing the cGMP levels.
20
5. The use as claimed in claim 4, where the disease is selected from a group of diseases consisting of dementia, stroke, craniocerebral trauma, Alzheimer's disease, dementia with degeneration of the frontal lobes, Lewy body dementia, vascular dementia, attention deficit syndrome, impairments of attention and concentration, Parkinson's disease, schizophrenia, depression, 25 affective disorders, psychoses, neuroses, anxiety, mania or manic depressive disorders, Pick's disease, pain and epilepsy.
6. The use as claimed in any of claims 1 to 5, where the selective PDE9A inhibitor is a compound of the formula
30



(I)

or



(II)

and the salts, solvates and solvates of the salts thereof.